The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma

The Oncologist
Emiliano CalvoBernard Escudier

Abstract

Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC). The VEGFR tyrosine kinase inhibitors (TKIs) pazopanib and sunitinib are FDA-approved first-line treatment options for advanced RCC; however, other treatment options in this setting are available, including the recently approved combination of nivolumab (anti-PD-1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein-4 [CTLA-4]) for patients with intermediate or poor risk. Unfortunately, treatment guideline recommendations provide little guidance to aid first-line treatment choice. In addition, several ongoing randomized phase III trials of investigational first-line regimens may complicate the RCC treatment paradigm if these agents gain approval. This article reviews clinical trial and real-world evidence for currently approved and investigational first-line treatment regimens for advanced RCC and provides clinical evidence to aid first-line treatment selection. IMPLICATIONS FOR PRACTICE: Vascular endothelial growth fa...Continue Reading

References

Jan 10, 2004·Clinical & Experimental Metastasis·Lesley J MurrayNancy K Pryer
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jan 10, 2008·Nature Biotechnology·Mazen W KaramanPatrick P Zarrinkar
Mar 4, 2008·Cancer Treatment Reviews·Kiran GuptaClaudie Charbonneau
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer S KoJames H Finke
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Oct 22, 2009·British Journal of Cancer·R KumarA G King
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
Aug 11, 2011·Current Clinical Pharmacology·Holleh D Husseinzadeh, Jorge A Garcia
Mar 21, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Mar 23, 2012·Nature Reviews. Cancer·Matthew Vanneman, Glenn Dranoff
Jan 17, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cora N SternbergIan D Davis
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc B Garnick
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerThomas E Hutson
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierDavid Cella
May 3, 2014·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Jan 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benoit BeuselinckJessica Zucman-Rossi
Apr 23, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thomas PowlesNeil Kaplowitz
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jul 29, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BracardaUNKNOWN Rainbow Group
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai

❮ Previous
Next ❯

Citations

Sep 6, 2019·Journal of Hematology & Oncology·Kevin ZarrabiShenhong Wu
Feb 6, 2020·International Journal of Molecular Sciences·João LoboRui Henrique
Mar 20, 2021·Nature Reviews. Disease Primers·Jean-Yves BlayMargaret von Mehren
Jun 9, 2021·Journal of Experimental & Clinical Cancer Research : CR·Revati SharmaNuzhat Ahmed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.